✦ For YouGeopoliticsTechFinanceHealthEnergySportsCulture◆ SN Last Week★ Saved

STAT+: Radiopharmaceutical shows promise in post-Pluvicto setting

By STAT News · Summarized & edited by · 2026-06-02
STAT+: Radiopharmaceutical shows promise in post-Pluvicto setting

Get the Health newsletter

Daily health & science — research, biotech, public health, the studies worth knowing. Free.

Abivax's ulcerative colitis data, Fulcrum's scrapped sickle cell drug, and more biotech news from The Readout

Share this story

𝕏 Twitter in LinkedIn 💬 WhatsApp
Ask SkimNews
More health → Read original →

Related stories

STAT+: Abivax ulcerative colitis drug shows strong efficacy, but cases of cancer raise concerns
STAT+: Abivax ulcerative colitis drug shows strong efficacy, but cases of cancer raise concerns Health
 STAT+: Talawar bets bispecific approach can shake up eczema market
STAT+: Talawar bets bispecific approach can shake up eczema market Health
 STAT+: Roche ends Huntington’s gene-silencing programs
STAT+: Roche ends Huntington’s gene-silencing programs Health
 STAT+: A standing ovation for RevMed, and caution for Akeso
STAT+: A standing ovation for RevMed, and caution for Akeso Health
 STAT+: Pharmalittle: We’re reading about a Parkinson’s drug setback, a Merck lung cancer therapy, and more
STAT+: Pharmalittle: We’re reading about a Parkinson’s drug setback, a Merck lung cancer therapy, and more Health

Get the Health newsletter

Curated health stories, every morning. Free.

No spam. Unsubscribe anytime.